SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors digest the announcement of a 2.48% rate increase for 2027 Medicare Advantage payments, a figure that significantly outperformed initial near-flat projections. The community is actively debating whether this news acts as a definitive bullish relief catalyst for the managed care sector or if underlying regulatory headwinds and volatility will continue to weigh on the stock's long-term outlook.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing intense downward pressure driven by a major analyst downgrade that warns of significant downside risk based on disappointing delivery figures and slowing demand. Investors are actively debating the stock's long-term valuation, with many traders pivoting toward aggressive put positions and hedging strategies while others speculate that capital is being rotated into the upcoming SpaceX IPO.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is seeing elevated bullish options activity and heightened community discourse as traders debate whether the stock is currently undergoing a technical accumulation phase or if ongoing manufacturing scaling challenges will continue to suppress price momentum. While speculative reports of a partnership with Meta-Bounds have fueled sentiment, investors remain focused on the company's ability to transition from pilot programs to high-volume commercial production.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana and other managed care providers surged following a final CMS ruling that offered a more favorable 2027 Medicare Advantage payment increase than the market initially feared. Investors and the community are now focused on how this relief rally will hold as they monitor potential earnings guidance adjustments and the sector's long-term margin recovery.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending following a major long-term agreement to develop and supply custom Tensor Processing Units for Google, alongside an expanded strategic collaboration that grants Anthropic access to significant AI compute capacity through 2031. While the community is actively debating whether this news justifies a fundamental rerating or if current price action reflects broader semiconductor sector caution, many investors remain bullish on Broadcom's central role in the AI infrastructure stack.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing intense volatility and downward pressure as the market reacts to a significant debt-related financing announcement and concerns over persistent high interest expenses. While the community is actively debating the stock's long-term sustainability due to its heavy debt load and potential for dilution, many traders are closely watching for a short squeeze setup, noting the stock's high institutional ownership and historical tendency for sudden, aggressive price swings.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is capturing significant community attention as investors debate its potential to evolve from a long-standing parody meme into a serious cultural asset. Participants are actively discussing its historical origins, the role of community-led narratives, and the speculative appeal of holding a coin that leans into its own contrarian identity.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing renewed investor interest driven by a successful $600 million AAA-rated ABS transaction and the addition of new institutional partners, reinforcing confidence in its AI-driven credit underwriting model. The community is actively discussing the stock's oversold technical setup and its potential for a recovery as the company continues to onboard new partners despite broader macro-economic and geopolitical headwinds.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate whether the stock is a deep-value play or a potential buyout candidate following reports of institutional activity and heavy short interest. The community remains divided, with some betting on a long-term turnaround fueled by international expansion, while others voice frustration over stagnant leadership and the lack of a permanent CEO.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health (ELV) is currently trending as investors weigh the impact of recent CMS sanctions and potential shifts in Medicare Advantage policies alongside broader sector volatility. Market participants are actively discussing the stock's valuation relative to its insurance peers, monitoring insider purchasing activity, and analyzing the potential for short-term price recovery following recent downward pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock.</li><li>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company announced an agreement with a major global pharmaceutical company.</li><li>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.</li></ul>U.S. equities were in the green in Tuesday’s pre-market trade after President Donald Trump reportedly indicated that he would be willing to end the Iran war without a complete reopening of the Strait of Hormuz.According to a report by The Wall Street Journal, President Trump told his aides about his willingness to end the war without getting Iran to reopen the strait following an assessment that this mission would result in prolonging the conflict beyond the four to six-week timeline.At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.92%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.86%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.94%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences Inc. (ARTL)</a>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock. Artelo stated that it intends to use the proceeds to repay a bridge debt and meet working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 139% year-to-date.<a href="https://stocktwits.com/symbol/BFRG">Bullfrog AI Holdings Inc. (BFRG)</a>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bfrg-stock-more-than-doubled-today-what-is-fueling-the-surge/cZERFnXRIZz">announced</a> an agreement with a major global pharmaceutical company to accelerate its drug discovery and clinical development programs.<a href="https://stocktwits.com/symbol/BFRG">BFRG stock</a> is up 19% year-to-date.<a href="https://stocktwits.com/symbol/HKIT">Hitek Global Inc. (HKIT)</a>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.<a href="https://stocktwits.com/symbol/HKIT">HKIT stock</a> is down 98% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-fed-iran-war-effects-not-facing-policy-decision-yet/cZERs6iRIN9">Powell Says Fed ‘Not Really Facing’ Policy Decision Yet Amid Iran Oil Shock – Adds Central Bank Will Be ‘Mindful Of The Broader Context’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

Equity

Medical Stocks To Research - March 27th

UnitedHealth Group, Artelo Biosciences, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Artelo Biosciences Stock Skyrockets 205%

(RTTNews) - Shares of Artelo Biosciences, Inc. (ARTL) are skyrocketing about 205 percent on Friday morning trading despite no corporate-related announcements to influence the movement...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Artelo Biosciences Targets GLP-1 Boom with Muscle Preservation Strategy as Stock Eyes Squeeze Potential

Artelo Biosciences (NASDAQ:ARTL) is expanding the development pathway for its lead candidate ART27.13, positioning the compound as a potential companion therapy to GLP-1 weight-loss drugs, one of the fastest-growing segments in biopharma.

<ul><li>Artelo indicated it will defer the planned securities offering for the moment.</li><li>The company confirmed no shares were sold and may consider fundraising later.</li><li>On Thursday, Artelo said it plans to test ART27.13 for preserving muscle in GLP-1 patients.</li></ul>Artelo Biosciences, Inc. (ARTL)&nbsp; has formally requested the withdrawal of its recently effective registration statement for a planned securities offering, signaling a pause in its capital-raising efforts.On Friday, the company submitted a request under Rule 477 of the Securities Act of 1933 to withdraw its Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.<h2 class="st-heading-2">Artelo Pauses Proposed Securities Offering</h2>Artelo stated that it does not plan to move forward with the proposed securities offering at this time.&nbsp;The company emphasized that no shares were issued or sold under the registration statement, and it intends to revisit capital-raising options in the future when conditions are more favorable.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences stock</a> traded over 420% higher on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;Additionally, the company announced a new private placement involving the sale of more than 3.18 million shares or equivalent pre-funded warrants. The transaction is expected to finalize around March 30, and the company expects gross proceeds of approximately $11 million.<h2 class="st-heading-2">Strategic Expansion Initiative</h2>On Thursday, Artelo announced plans to explore a new application for its ART27.13 compound. The therapy targets muscle preservation in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist treatment to address lean body mass loss.&nbsp;The initiative builds on multiple promising developments. ART27.13 demonstrated protective effects on muscle in the CAReS trial, showing increased lean body mass and enhanced physical activity in cancer anorexia and cachexia patients.Artelo Biosciences is a clinical-stage pharmaceutical company focused on treatments for cancer, pain, dermatologic, and neurological conditions.ARTL stock has gained over 170% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/entergy-meta-ink-agreement-to-fund-new-gas-plants-for-louisiana-ai-data-center/cZ3H5r4RImT">Entergy, Meta Ink Agreement To Fund New Gas Plants For Louisiana AI Data Center</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

 Why Did ARTL Stock Skyrocket Over 420% Today? 

Artelo requested withdrawal of its Form S-1, effective March 25, and will not proceed with the planned securities offering.

Small Cap Stocks To Watch Now - March 18th

AltC Acquisition, Direxion Daily MU Bull 2X Shares, and Artelo Biosciences are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of...

Nano-Cap Artelo Biosciences Stock Explodes Glaucoma Study Collaboration Ignites Rally

Artelo Biosciences shares jump after a glaucoma study deal to test ART27.13, a new treatment targeting eye pressure in patients.read more...

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul><li>Artelo is developing ART27.13, which is a synthetic drug that targets cannabinoid receptors, but only outside the brain.</li><li>The company said preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow.</li><li>Artelo is developing ART27.13 as a once-daily oral drug that could improve body weight, appetite, muscle degeneration, and overall quality of life in cancer patients.</li></ul>&nbsp;Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R&amp;D Division.The study will evaluate the effects of Artelo’s peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences shares</a> were up more than 33% in Wednesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.—What Is The ART27.13 Treatment?ART27.13 is a synthetic drug that targets cannabinoid receptors, but only outside the brain. The company stated that preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow. These are the two key mechanisms involved in intraocular pressure regulation.“The ophthalmology community has long recognized the potential of cannabinoids in managing intraocular pressure, but their use has been limited by central nervous system effects. ART27.13’s peripherally selective design may overcome this challenge,” said Artelo CEO Greg D. Gorgas.The company is developing ART27.13 as a once-daily, orally administered drug. Artelo says it has the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients.What Does Artelo Do?Artelo is a California-based clinical-stage pharmaceutical company currently developing and commercializing proprietary therapeutics that modulate how fat-based molecules signal between cells.The company has a diversified pipeline of therapeutics for patients with anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 75% year-to-date, but down 61% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 18% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palladyne-ai-subsidiary-wins-us-navy-contract-for-near-hypersonic-missiles/cZ379ezRIgL">Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ARTL Stock Soaring Today?

Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARTL News

ARTLArtelo Biosciences Inc